A prominent feature of breast cancer with low HER2 expression was a sizeable increase in the positive rate of HR compared with HER2-zero counterparts (92.31% vs. 70.39%, p < 0.001), which was relatively higher than other reported data (64.0%–90.2%) (12, 13, 16, 22). This evidence concerns the gene ERBB2 and breast carcinoma.